Friedrich Bohlen

Prof. Friedrich von Bohlen, Ph.D., founded Molecular Health AG and serves as its Chairman and Chief Executive Officer. Prof. Friedrich von Bohlen Co-Founder Dievini GmbH and has been its Managing Director since 2005. He Co-Founded dievini Hopp BioTech holding GmbH & Co. KG. and serves as its Managing Director. He served as the Chief Executive Officer and Chairman of Management Board of Agennix AG until February 28, 2011. He Co-Founded Lion Bioscience AG. He served as Chairman of Management Board and Chief Executive Officer of Sygnis Pharma AG (Formerly known as Lion Bioscience AG ) from March 1997 to December 31, 2003. Prof. Friedrich von Bohlen served as the Chief Executive Officer of WASAG Chemie AG Essen. He served as a Member of Management Board at Sygnis Pharma AG from March 1997 to December 31, 2003. Before joining WASAG, he held the position of an Assistant to the Chairman of the management board of FAG Kugelfischer KGaA, Schweinfurt, Germany. He more than 10 years of entrepreneurial experience in the Life Sciences Industry He started his career as a Trainee in Research and Development at Fresenius AG, Oberursel, Germany. He serves as the Chairman of Advisory Board at Apogenix GmbH. He serves as the Chairman of the Board of CureVac GmbH. He serves as the Chairman of Supervisory Board of CureVac GmbH. He served as the Chairman of Supervisory Board at Sygnis Pharma AG from November 3, 2004 to October 17, 2012.